mTOR inhibitor as off-label option in treatment of progressive refractory nasopharyngeal carcinoma
https://doi.org/10.17650/2222-1468-2025-15-3-124-130
Abstract
Nasopharyngeal carcinoma (NpC) is a malignant tumor developing from the non-keratinizing epithelium of the nasopharynx. In 2022, more that 530,000 new NpC cases were registered worldwide. The rate of NpC in the Russian federation reaches 0.3 % among all malignancies and up to 2 % of head and neck cancers. The 5-year overall survival rate varies from 90 % in patients with stage I NpC to 40 % in those with stage Iv NpC. Over 40 % of newly diagnosed NpC patients already have stage Iv disease.
In this article, we report a case of successful treatment of a patient with locally advanced recurrent nasopharyngeal carcinoma.
About the Authors
A. M. Mudunov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; Sechenov University, Ministry of Health of Russia
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow Region 143081
Bld. 2, 8 Trubetskaya St., Moscow 11999
A. M. Khabazov
Specialized Medical Center of the Bank of Russia
Russian Federation
Russian Federation
66 Sevastopolsky Prospekt, 116152 Moscow
M. B. Pak
Specialized Medical Center of the Bank of Russia
Russian Federation
Russian Federation
Maxim Bokmanovich Pak
66 Sevastopolsky Prospekt, 116152 Moscow
S. V. Berelavichus
Specialized Medical Center of the Bank of Russia
Russian Federation
Russian Federation
66 Sevastopolsky Prospekt, 116152 Moscow
H. Chen
Beijing Chao-Yang hospital, Capital Medical University
China
China
8 South Gongren Gymnasium Road, Chaoyang District, Beijing 100006
References
1. Encyclopedia of clinical Oncology: basic tools and methods for the diagnosis and treatment of malignant neoplasms. Ed. by M.I. Davydov. Moscow: RADAR-2004, 2004. 1456 p. (In Russ.).
2. Yang Y., Qu S., Li J. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology 2021;22(8):1162–74. DOI: 10.1016/S1470-2045(21)00302-8
3. Al-Anazi A., Alanazi B., Alshanbari H.M. et al. Increased prevalence of EBV infection in nasopharyngeal carcinoma patients: a six-year cross-sectional study. Cancers (Basel) 2023;15(3):643. DOI: 10.3390/cancers15030643
4. Zhang J., Fang W., Qin T. et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol 2015;32(3):86. DOI: 10.1155/2022/8537966
5. Blanchard P., Lee A., Marguet S. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16(6):645–55. DOI: 10.1016/S1470-2045(15)70126-9
6. Zhang Y., Li W.F., Liu X. et al. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: analysis of a multicenter, phase III randomized trial. Radiother Oncol 2018;129(1):18–22. DOI: 10.1016/j.radonc.2017.12.002
7. Ribassin-Majed L., Marguet S., Lee A.W. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35(5):498–505. DOI: 10.1200/JCO.2016.67.4119
8. Chua D.T., Wei W.I., Sham J.S. et al. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma. Head Neck 2003;25(7):585–94. DOI: 10.1002/hed.10242
9. Toumi N., Ennouri S., Charfeddine I. et al. Local and lymph node relapse of nasopharyngeal carcinoma: a single-center experience. Ear Nose Throat J 2020;100(Suppl 5):795S–800S. DOI: 10.1177/0145561320908955
10. Poh S.S., Soong Y.L., Sommat K. et al. Retreatment in locally recurrent nasopharyngeal carcinoma: current status and perspectives. Cancer Commun (Lond) 2021;4(5):361–70. DOI: 10.1002/cac2.12159
11. Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2):160–82. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-1.1-09
12. Shi S., Li B., Zhou P. et al. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer. Cancer Med 2024;13(14):e7359. DOI: 10.1002/cam4.7359
13. Zhou Z., Li P. et al. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes. Mol Med 2022;28(1):55. DOI: 10.1186/s10020-022-00479-4
14. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–7. DOI: 10.1038/nature11252
15. Zehir A., Benayed R., Shah R.H. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23(6):703–13. DOI: 10.1038/nm.4333
16. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129
17. Cheaib B., Auguste A., Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 2015;34(1):4–16. DOI: 10.5732/cjc.014.10289
18. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489–501. DOI: 10.1038/nrc839
19. Bessiere L., Todeschini A.-L. et al. A Hot-spot of In-frame ̀ duplications activates the oncoprotein AKT1 in juvenile granulosa cell tumors. eBioMedicine 2015;2(5):421–31. DOI: 10.1016/j.ebiom.2015.03.002
20. Auguste A., Bessiere L., Auguste A. et al. Molecular analyses ̀ of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads. Hum Mol Genet 2015;24(23):6687–98. DOI: 10.1093/hmg/ddv373
21. Chang M.T., Bhattarai T.S., Schram A.M. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 2018;8(2):174–83. DOI: 10.1158/2159-8290.CD-17-0321
22. Yeh Y.-C., Ho H.-L., Wu Y.C. et al. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Mod Pathol 2020;33(3):391–403. DOI: 10.1038/s41379-019-0357-y
23. Parikh C., Janakiraman V., Wu W.I. et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci USA 2012;109(47):19368–73. DOI: 10.1073/pnas.1204384109
24. Calleja V., Laguerre M., Parker P.J., Larijani B. et al. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7(1):e17. DOI: 10.1371/journal.pbio.1000017
25. Smyth L.M., Tamura K., Oliveira M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1E17K-mutant, ER-positive metastatic breast cancer. Clin Cancer Res 2020;26(15):3947–57. DOI: 10.1158/1078-0432.CCR-19-3953
26. Kalinsky K., Zihan W., Kalinsky K. et al. Ipatasertib in patients with tumors with AKT mutations: results from the NCI-MATCH ECOG-ACRIn trial (EAY131) sub-protocol Z1K. Clin Cancer Res 2025. DOI: 10.1158/1078-0432.CCR-24-3431
27. Yu Z., Wei W., Liu H. et al. Efficient everolimus treatment for metastatic castration resistant prostate cancer with akt1 mutation: a case report. Onco Targets Ther 2021;14:5423–8. DOI: 10.2147/OTT.S334205
28. Giannakis M., Mu X.J., Shukla S.A. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 2016;15(4):857–65. DOI: 10.1016/j.celrep.2016.03.075
29. Tredan O., Treilleux I., Wang Q. et al. Predicting everolimus ́ treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol 2013;8(4):243–51. DOI: 10.1007/s11523-012-0242-9
30. Schneider T.C., de Wit D., Links T.P. et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocrinol Metab 2017;102(2):698–707. DOI: 10.1210/jc.2016-2525
31. Bryce A.H., Egan J.B., Borad M.J. et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget 2017;8(16):27145–54. DOI: 10.18632/oncotarget.16057
Review
For citations:
Mudunov A.M., Khabazov A.M., Pak M.B., Berelavichus S.V., Chen H. mTOR inhibitor as off-label option in treatment of progressive refractory nasopharyngeal carcinoma. Head and Neck Tumors (HNT). 2025;15(3):124-130. https://doi.org/10.17650/2222-1468-2025-15-3-124-130
Views:
7
Email this article 